drugset / Trial / NCT03244956
Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a multicentric prospective non-randomized phase II trial, with two independent arms: one for patients with RAS mutation and one for patients with BRAFV600E mutation.
Timeline
- Start
- 2017-12-27
- Primary completion
- 2022-05-23
- Completion
- 2026-01-15
Publications
- Anizan N, Pignard A, Borget I, Lamartina L, Schlumberger M, Broggio D, Leboulleux S, Lamart S. Lesional dosimetry in 131I refractory metastatic differentiated thyroid cancer with BRAFp.V600E or RAS mutation treated with trametinib +/- dabrafenib followed by radioactive iodine. Phys Med. 2026 May;145:105769. doi: 10.1016/j.ejmp.2026.105769. Epub 2026 Mar 19.
- Leboulleux S, Benisvy D, Taieb D, Attard M, Bournaud C, Terroir-Cassou-Mounat M, Lacroix L, Anizan N, Schiazza A, Garcia ME, Ghuzlan AA, Lamartina L, Schlumberger M, Godbert Y, Borget I. MERAIODE: A Phase II Redifferentiation Trial with Trametinib and 131I in Metastatic Radioactive Iodine Refractory RAS Mutated Differentiated Thyroid Cancer. Thyroid. 2023 Sep;33(9):1124-1129. doi: 10.1089/thy.2023.0240. Epub 2023 Jul 26. No abstract available.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dabrafenib | Small molecule | 150 mg | — |
| Subject | Trametinib | Small molecule | 2 mg | — |
| Background | rhTSH | Protein / enzyme biologic | 0.9 mg | — |